NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Drug Manufacturers - Specialty & Generic · USD

RedHill Biopharma Ltd. (RDHL) Stock Analysis

RedHill Biopharma Ltd. (RDHL) is a Drug Manufacturers - Specialty & Generic stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

RDHL

$0.46

−$0.05 (−10.31%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare RDHL with… →

RDHL Key Statistics

As of Oct 21, 2026
Trading
Open
$0.47
Previous Close
$0.51
Day's Range
0.46–0.49
52-Week Range
0.44–1.90
Volume
127.15K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
4.90
Valuation
Market Cap
$4.04M
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
15.17
EPS (ttm)Profit attributable to each share over the last twelve months.
0.00
Financials (FY)
Revenue (FY)
$286.00K
Net Income (FY)
−$429.00K
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
8.89M
1-Year Return
−74.72%
Dividend and dates
Avg Volume
2.06M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, RDHL closed at $0.46, −74.72% over 1 year.

RedHill Biopharma Ltd. (RDHL) has a market capitalization of $4.04M.

In fiscal 2025, RDHL reported revenue of $286.00K.

RDHL Stock Return by Calendar Year

RedHill Biopharma Ltd. (RDHL) 10-year return: what $10,000 became

1 year
$10,000 $2,528
−74.72%
5 years
$10,000 $0.80
−99.99%
10 years
$10,000 $0.33
−99.997%

If you had invested $10,000 in RedHill Biopharma Ltd. (RDHL) 10 years ago, at the close on October 21, 2016, it would have been worth $0.33 at the close on October 21, 2026: −99.997% in total, −64.36% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−55.83%
2025−83.41%
2024−82.99%
2023−73.93%
2022−94.57%
2021−68.07%
2020+33.11%
2019+9.37%
2018+7.98%
2017−50.86%
2016 (partial year)−31.81%

As of October 21, 2026.

RDHL Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$286.00K−$429.00K−150.0%
2024$0.00−$8.27M—
2023$0.00$23.92M—
2022$61.80M−$71.67M−116.0%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$286.00K—−$7.91M−$429.00K−150.0%
2024$0.00$4.85M−$6.48M−$8.27M—
2023$0.00$3.07M−$9.55M$23.92M—
2022$61.80M$28.46M−$42.84M−$71.67M−116.0%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 11 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

RedHill Biopharma Ltd. (RDHL) is capitalised at $4.04M on the latest close. It is classified in the Drug Manufacturers - Specialty & Generic industry, within the Healthcare sector. The company reports 13 employees.

The 52-week range on file runs from $0.44 to $1.90. RDHL last closed at $0.46 on October 21, 2026. That is −$0.05 (−10.31%) against the previous close. The latest close sits 4.6% above that 52-week low.

Financial Health

In fiscal 2025, RedHill Biopharma Ltd. reported revenue of $286.00K. The same year closed with a net loss of $429.00K. Trailing earnings per share are 0.

Across the 4 fiscal years on file, revenue moves from $61.80M in 2022 to $286.00K in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

On forward earnings the ratio is 15.17.

Beta against the wider market is reported at 4.9. Annualized volatility over the trailing 10 years is 123.43%. The trailing one-year total return is −74.72%. Measured over 10 years, that is −64.36% a year compounded.

Growth & Income

No dividend is on file for RDHL.

The strongest complete calendar year on file is 2020 at +33.11%; the weakest is 2022 at −94.57%. Of the 9 complete calendar years on file, 3 finished higher. So far in 2026 the total return is −55.83%.

Peer Comparison

RedHill Biopharma Ltd. (RDHL) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
RedHill Biopharma Ltd. RDHL $4.04M —
Takeda Pharmaceutical Company Limited TAK $63.67B —
Teva Pharmaceutical Industries Limited TEVA $47.37B 67.7
Haleon plc HLN $44.06B 20.5

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 20.3x. RedHill Biopharma Ltd. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$63.67B

 TEVA

Teva Pharmaceutical Industries Limited

$47.37B

 HLN

Haleon plc

$44.06B

 ZTS

Zoetis Inc.

$32.90B

 UTHR

United Therapeutics Corporation

$24.17B

 VTRS

Viatris Inc.

$21.19B
View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About RedHill Biopharma Ltd.

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, prostate cancer, nuclear radiation protection; and host directed anti-viral; Rebyota, a microbiota-based therapy for prevention of recurrent Clostridioides difficile infection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 that is in Phase 3 clinical trial for the treatment of pulmonary Mycobacterium avium complex disease in adults. It also commercializes Clenpiq, a ready-to-drink low-volume bowel preparation. The company was incorporated in 2009 and is headquartered in Tel Aviv-Yafo, Israel.

Visit website →